- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | DelveInsight Business Research, LLP: Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Harmony Biosciences | 387 | PR Newswire | The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be further influenced by the extensive pipeline... ► Artikel lesen | |
| 05.06. | Harmony Biosciences Presents Positive Data For Pitolisant In The Treatment Of Excessive Daytime Sleepiness And Fatigue In Myotonic Dystrophy Type 1 | 42 | PR Newswire | PLYMOUTH MEETING, Pa., June 5, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness... ► Artikel lesen | |
| 29.05. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View | 2 | Benzinga.com | ||
| 30.04. | Harmony Biosciences Holdings Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 30.04. | Key Takeaways From Harmony Biosciences Analyst Ratings | 1 | Benzinga.com | ||
| 30.04. | Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline | 2 | Seeking Alpha | ||
| 30.04. | Harmony Biosciences Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.04. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M | 2 | Seeking Alpha | ||
| 30.04. | Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy | 120 | GlobeNewswire (Europe) | WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half... ► Artikel lesen | |
| 30.04. | Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets | 96 | PR Newswire | Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations
EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026
Plan to Initiate Phase... ► Artikel lesen | |
| 29.04. | Harmony Biosciences Q1 2024 Earnings Preview | 1 | Seeking Alpha | ||
| 11.04. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.04. | Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist | 122 | PR Newswire | PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and... ► Artikel lesen | |
| 03.04. | Harmony Biosciences Initiates Global Phase 3 Registrational Trial (tempo Study) Of Pitolisant In Patients With Prader-willi Syndrome | 102 | PR Newswire | PLYMOUTH MEETING, Pa., April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate... ► Artikel lesen | |
| 28.03. | Evaluating Harmony Biosciences: Insights From 8 Financial Analysts | 1 | Benzinga.com | ||
| 19.03. | Harmony Biosciences exec sells over $383k in stock | 1 | Investing.com | ||
| 28.02. | Harmony Biosciences Holdings, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 23.02. | Earnings call: Harmony Biosciences reports 2023 growth driven by WAKIX | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,010 | -25,46 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 56,50 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.03.2024 - 4 | The following instruments on Boerse Frankfurt do have their last trading day on 14.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.03.2024ISIN NameCH0305285295 VARIA... ► Artikel lesen | |
| MAINZ BIOMED | 0,548 | +2,24 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! copy | ||
| DEFENCE THERAPEUTICS | 0,612 | +0,66 % | EQS-News: Defence Therapeutics Inc.: Der wissenschaftliche Leiter von Defence, Dr. Moutih Rafei, spricht auf Money Talk Radio mit Ellis Martin über die Accum-Platform zur Krebsbekämpfung | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DER WISSENSCHAFTLICHE LEITER VON DEFENCE, DR. MOUTIH RAFEI, SPRICHT AUF MONEY TALK RADIO MIT... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 121,40 | -0,41 % | Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans | ||
| GINKGO BIOWORKS | 0,392 | -0,51 % | Ginkgo Bioworks Holdings, Inc. - 8-K, Current Report | ||
| HALOZYME THERAPEUTICS | 46,140 | -1,41 % | Halozyme Therapeutics, Inc.: Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook | Company Granted New European Patent for ENHANZE® Drug Delivery Platform
SAN DIEGO, June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,170 | 0,00 % | Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease | MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 9,700 | +3,52 % | Recursion Pharmaceuticals: Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry | SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion... ► Artikel lesen | |
| ARGENX | 353,90 | 0,00 % | argenx SE: argenx to unveil its 'Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on July 16, 2024 | R&D Day presentations to include recent Phase 2 datasets in Sjogren's disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action | Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program
Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism... ► Artikel lesen | |
| ARDELYX | 5,540 | +0,07 % | ARDELYX, INC. - 8-K, Current Report | ||
| ASSERTIO | 1,095 | +4,29 % | Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying | ||
| ARCTURUS THERAPEUTICS | 25,960 | 0,00 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 8,950 | -2,51 % | Vir Biotechnology, Inc.: Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 | - Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial - - Conference call scheduled for June 5, 2024, at 6:00 a.m. ET 12:00 p.m. CEST -
Vir Biotechnology... ► Artikel lesen |
Das Unternehmen HARMONY BIOSCIENCES HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,65 % bei einem Aktienkurs von 28,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
